The frequency of high-risk human papillomavirus (hr-HPV) genotypes in patients with adenocarcinoma in situ (ACIS) with coexisting cervical intraepithelial neoplasia (CIN), ACIS without coexisting CIN, ...
On Feb 27, 2012, Advaxis (OTC:ADXS) announced that it has completed the first of 3 dose cohorts in the single blind, placebo controlled Phase II dose escalation study assessing the safety and efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results